Top stories in hematology/oncology: Lung cancer management during COVID-19, PPIs linked to cognitive decline in breast cancer survivors
Click Here to Manage Email Alerts
In a recent interview, Jacob Sands, MD, oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, spoke with Healio about the impact of COVID-19 on the management of patients with lung cancer. It was the top story in hematology/oncology last week.
Another top story was a feature exploring the link between proton pump inhibitors (PPIs) and cognitive decline among breast cancer survivors, who often take PPIs to manage gastrointestinal symptoms.
Read these and more top stories in hematology/oncology below:
Lung cancer management in the COVID-19 era requires an individualized approach
Amid the COVID-19 pandemic, it is important to pay close attention to individual clinical and radiological pulmonary signs of patients with lung cancer while awaiting specific evidence-based treatment guidelines. Read more.
PPIs may lead to cognitive decline among breast cancer survivors
Breast cancer survivors often take PPIs to manage gastrointestinal symptoms related to their treatment. Physicians also may recommend longer-term use of PPIs to protect the gastric mucosal layer, which can deteriorate as a result of chemotherapy. Read more.
VIDEO: Lessons learned during COVID-19 pandemic may provide lasting benefits
Edward S. Kim, MD, chair of the department of solid tumor oncology and investigational therapeutics at Levine Cancer Institute at Atrium Health, spoke with Healio about how COVID-19 has affected cancer care delivery. Watch video.
COVID-19 pandemic prompts emergency radiation therapy guidelines for hematologic malignancies
An International Lymphoma Radiation Oncology Group task force has developed emergency recommendations for the management of radiation therapy for patients with hematologic malignancies during the COVID-19 pandemic. Read more.
FDA approves Trodelvy for metastatic triple-negative breast cancer
The FDA granted accelerated approval to sacituzumab govitecan-hziy (Trodelvy, Immunomedics) for the treatment of certain adults with metastatic triple-negative breast cancer. Read more.